Edinburgh-based Craneware plc, a provider of software for the US healthcare market, said on Friday its alliance with Microsoft is progressing well and “adding significant sales pipeline growth as well as continuing to help drive innovation.”
In a trading update for its AGM, Craneware said that following the growth reported in FY25, the start of FY26 has seen the positive momentum continue.
“Alongside the Group’s direct sales efforts, the alliance with Microsoft is progressing well, adding significant sales pipeline growth as well as continuing to help drive innovation,” said the Edinburgh firm.
“US healthcare providers remain focused on optimising their operational and financial performance, driving demand for the Group’s solutions.
“The Group continues to invest in R&D to strengthen its product set, leveraging its proprietary data assets to expand its offerings and launch new AI enabled applications.
“A recent area of focus has been the accelerated development of a product to support customers through the 340B drug rebate pilot program, whereby participating hospitals have to purchase an initial 9 named drugs at wholesale acquisition cost and later apply for manufacturer rebates.
“This program, announced on 30 October 2025 by the Health Resources and Services Administration (“HRSA”), is due to commence on 1 January 2026, creating further operational and administrative complexities for healthcare providers.
“As a result of prior investments in the Trisus platform, the depth of Craneware’s data and its unique position of independence in the 340B vendor market, the Company has successfully brought this fully integrated solution to market in an accelerated timeframe, supporting its customers by reducing their financial risk, maintaining compliance and protecting resources for patient care.
“Having demonstrated the product through live meetings and a series of webinars, the solution is now being rolled out ahead of the deadline and is a testament to Craneware’s leading position in the 340B market.”
Conforming board changes, Craneware said: “As previously announced, following many years of service on the Board of Directors, David Kemp, Senior Non-Executive Director, has decided not to stand for re-election at the Company’s AGM later today and as a result, will retire from the Board following the close of the meeting.
“The Board thanks him for his significant contributions during his tenure. His insight and constructive challenge have been invaluable, helping drive Craneware’s success.
“Following the completion of the AGM, Alistair Erskine will assume the role of Senior Independent Director, Susan Nelson will assume the role of Chair of the Audit Committee and Jill Goldsmith will take over the role of Company Secretary to the Board.”
In its outlook, Craneware said: “The strength of the Company’s Annuity SaaS business model and balance sheet, its high levels of recurring revenue and strong cash generation provide Craneware with solid foundations as it executes on its growth strategy and the creation of long-term value for all stakeholders.
“The Board remains confident in the delivery of continued growth over the near term, and the Group continues to trade in line with market expectations for the year.”